Study of a new drug combo for head and neck cancer before surgery
Part of Cancer clinical trials.
This trial tests a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery for head and neck cancer that has not spread far. The goal is to see if this treatment shrinks tumors and improves outcomes for patients with stage 3 or 4A disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a type of head and neck cancer called squamous cell carcinoma, in specific areas like the mouth, throat, or voice box.
- You have not received any prior treatment for your current cancer.
- You are healthy enough for daily activities (ECOG score 0 or 1) and expected to live at least 6 months.
- You do not have an active autoimmune disease or another cancer.
- You have adequate organ function, such as kidney, liver, and blood cell counts within normal ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (antibody-drug conjugate) alone or with an immunotherapy drug before surgery for head and neck cancer that can be removed. The goal is to see if this combination shrinks the tumor and improves outcomes.
This trial tests two new cancer-fighting drugs (becotatug vedotin and pucotenlimab) given together before surgery to treat head and neck cancer that has come back and stopped responding to previous immunotherapy. The goal is to shrink the tumor enough to make surgery safer and more effective.
This trial tests a new drug combo—becotatug vedotin plus a PD-1 inhibitor—for people with head and neck squamous cell cancer that cannot be surgically removed. It aims to see if this treatment can shrink tumors or slow their growth.
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
This trial tests a combination of three drugs (tirelizumab, carboplatin, and a special form of paclitaxel) given before surgery to treat advanced head and neck cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a combination of three drugs (MRG003, pucotenlimab, and possibly cisplatin) given before surgery for people with a specific type of head and neck cancer that is EGFR-positive and has not been treated yet. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.